醒脑静注射液治疗急性脑梗死的临床观察
x
请在关注微信后,向客服人员索取文件
篇名: | 醒脑静注射液治疗急性脑梗死的临床观察 |
TITLE: | |
摘要: | 目的: 探讨醒脑静注射液对急性脑梗死患者的临床疗效及安全性,以及对患者神经功能、生活活动能力、炎症细胞因子和昏迷度评分的影响。方法: 选取2015年6月-2016年1月重庆市人民医院收治的脑梗死患者90例。按照随机数字表法分为对照组和观察组,各45例。对照组患者进行常规治疗,给予硫酸氢氯吡格雷片75 mg,po,qd+尼莫地平片20 mg,po,tid;观察组患者在此基础上给予醒脑静注射液20 mL加至0.9%氯化钠注射液250 mL中,ivgtt,qd。两组患者均连续治疗14 d。观察两组患者临床疗效,治疗前后美国国立卫生研究院卒中量表(NIHSS)、Barthel指数和Glasow昏迷度评定量表评分以及肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)水平,并记录不良反应发生情况。结果: 观察组患者临床总有效率(91.11%)显著高于对照组(73.33%),差异有统计学意义(P<0.05)。治疗前,两组患者NIHSS、Barthel指数和Glasow昏迷度评定量表评分以及TNF-α和IL-6水平比较,差异均无统计学意义(P>0.05)。治疗后,两组患者NIHSS评分、TNF-α及IL-6水平显著降低,Barthel指数显著升高,且观察组患者上述指标改善程度均显著优于对照组,差异均有统计学意义(P<0.05);治疗14 d后,对照组患者Glasow昏迷度评分显著高于治疗前;治疗1、5、14 d后,观察组患者Glasow昏迷度评分显著高于治疗前,且显著高于对照组,差异均有统计学意义(P<0.05)。观察组患者的总不良反应发生率(6.67%)显著低于对照组(13.33%),差异有统计学意义(P<0.05)。结论: 醒脑静注射液治疗急性脑梗死患者的临床疗效显著,能有效改善患者的神经功能和生活活动能力,促进患者苏醒,降低炎症因子水平,且安全性较高。 |
ABSTRACT: | OBJECTIVE: To investigate clinical efficacy and safety of Xingnaojing injection in the treatment of acute cerebral infarction, and its effects on neurological function, activities of living, inflammatory factors and coma score. METHODS: Ninety patients with cerebral infarction admitted in Chongqing People’s Hospital from Jun. 2015 to Jan. 2016 were divided into control group and observation group according to random number table, with 45 cases in each group. Control group was given conventional treatment as Clopidogrel bisulfate tablets 75 mg,po,qd+ Nimodipine tablets 20 mg,po,tid. Observation group was additionally given Xingnaojing injection 20 mL added into 0.9% Sodium chloride solution 250 mL, ivgtt, qd, on the basis of control group. Both groups received treatment for consecutive 14 d. Clinical efficacies of 2 groups were observed. NIHSS scores, Barthel indexes, Glasow coma scale and the levels of TNF-α and IL-6 were also observed before and after treatment. The occurrence of ADR was recorded. RESULTS: The total response rate of observation group (91.11%) was significantly higher than that of control group (73.33%), with statistical significance (P<0.05). Before treatment, there was no statistical significance in NIHSS scores, Barthel indexes, Glasow coma scale or the levels of TNF-α and IL-6 between 2 groups (P>0.05). After treatment, NIHSS scores, the levels of TNF-α and IL-6 in 2 groups were decreased significantly, while Barthel indexes were increased significantly; the improvement of above indexes in observation group were significantly better than control group, with statistical significance (P<0.05). Fourteen days after treatment, Glasow coma scale of control group was significantly higher than before treatment; 1, 5, 14 d after treatment, Glasow coma scale of observation group was significantly higher than before treatment, and significantly higher than that of control group, with statistical significance (P<0.05). Total incidence of ADR in observation group (6.67%) was significantly lower than control group (13.33%), with statistical significance (P<0.05). CONCLUSIONS: Xingnaojing injection shows significant therapeutic efficacy for acute cerebral infarction, can effectively improve the neurological function, activities of living, the regain of consciousness, and can reduce the level of inflammatory factor with good safety. |
期刊: | 2017年第28卷第32期 |
作者: | 封杰,车福友,张萌 |
AUTHORS: | FENG Jie,CHE Fuyou,ZHANG Meng |
关键字: | 醒脑静注射液;急性脑梗死;神经功能;生活活动能力;肿瘤坏死因子α;白细胞介素6 |
KEYWORDS: | Xingnaojing injection; Acute cerebral infarction; Neurological function; Activities of living; TNF-α; IL-6 |
阅读数: | 318 次 |
本月下载数: | 0 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!